Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $8.24 billion. The enterprise value is $7.27 billion.
Market Cap | 8.24B |
Enterprise Value | 7.27B |
Important Dates
The last earnings date was Monday, May 13, 2024, before market open.
Earnings Date | May 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 182.28 million shares outstanding.
Shares Outstanding | 182.28M |
Owned by Insiders (%) | 1.32% |
Owned by Institutions (%) | 49.02% |
Float | 159.53M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 24.03 |
Forward PS | 12.78 |
PB Ratio | 7.08 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 21.21 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.66, with a Debt / Equity ratio of 0.29.
Current Ratio | 5.66 |
Quick Ratio | 5.23 |
Debt / Equity | 0.29 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -20.12 |
Financial Efficiency
Return on equity (ROE) is -36.10% and return on invested capital (ROIC) is -21.47%.
Return on Equity (ROE) | -36.10% |
Return on Assets (ROA) | -25.20% |
Return on Capital (ROIC) | -21.47% |
Revenue Per Employee | $187,732 |
Profits Per Employee | -$255,173 |
Employee Count | 1,826 |
Asset Turnover | 0.19 |
Inventory Turnover | 9.52 |
Taxes
Income Tax | -1.99M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.71% in the last 52 weeks. The beta is 0.12, so Legend Biotech's price volatility has been lower than the market average.
Beta (1Y) | 0.12 |
52-Week Price Change | -36.71% |
50-Day Moving Average | 52.48 |
200-Day Moving Average | 60.80 |
Relative Strength Index (RSI) | 41.28 |
Average Volume (30 Days) | 1,029,680 |
Short Selling Information
Short Interest | 13.28M |
Short Previous Month | 10.98M |
Short % of Shares Out | 14.05% |
Short % of Float | n/a |
Short Ratio (days to cover) | 12.04 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $342.80 million and -$465.95 million in losses. Loss per share was -$2.58.
Revenue | 342.80M |
Gross Profit | 179.46M |
Operating Income | -321.74M |
Pretax Income | -467.93M |
Net Income | -465.95M |
EBITDA | n/a |
EBIT | -445.78M |
Loss Per Share | -$2.58 |
Balance Sheet
The company has $1.30 billion in cash and $334.69 million in debt, giving a net cash position of $968.05 million or $5.31 per share.
Cash & Cash Equivalents | 1.30B |
Total Debt | 334.69M |
Net Cash | 968.05M |
Net Cash Per Share | $5.31 |
Equity / Book Value | 1.16B |
Book Value Per Share | 6.39 |
Working Capital | 1.16B |
Cash Flow
In the last 12 months, operating cash flow was -$296.03 million and capital expenditures -$27.17 million, giving a free cash flow of -$323.20 million.
Operating Cash Flow | -296.03M |
Capital Expenditures | -27.17M |
Free Cash Flow | -323.20M |
FCF Per Share | -$1.78 |
Margins
Gross margin is 52.35%, with operating and profit margins of -93.86% and -135.92%.
Gross Margin | 52.35% |
Operating Margin | -93.86% |
Pretax Margin | -136.50% |
Profit Margin | -135.92% |
EBITDA Margin | n/a |
EBIT Margin | -130.04% |
FCF Margin | -94.28% |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -10.08% |
Shareholder Yield | -10.08% |
Earnings Yield | -5.66% |
FCF Yield | -3.92% |
Analyst Forecast
The average price target for Legend Biotech is $83.89, which is 85.76% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $83.89 |
Price Target Difference | 85.76% |
Analyst Consensus | Strong Buy |
Analyst Count | 11 |
Revenue Growth Forecast (5Y) | 58.68% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 4 |